Glycaemic traits fasting insulin (FI), fasting glucose (FG), 2-hour glucose (2hGlu) and glycated haemoglobin (HbA1c) are used to diagnose and monitor type 2 diabetes (T2D). MAGIC (Meta-Analysis of Glucose and Insulin-related traits Consortium) identified 242 loci associated with these traits in 281,416 individuals, from 6 ancestries. European (EUR) ancestry fine-mapping resulted in credible sets accounting for 99% of the posterior probability of association (99CS) with a median of 55 SNPs. Trans-ancestry (TA) fine-mapping led to 99CS with a median of 45 SNPs. Here, we investigated whether fine-mapping resolution could be improved by leveraging data across multiple related traits. We used the novel method FLexible And SHared information Fine-Mapping (flashfm), which takes advantage of sharing of information between traits. We compared its performance with single-trait FINEMAP results. We conducted EUR fine-mapping for 53 loci associated with ≥2 glycaemic traits (p<10-6, N=119 loci-trait associations). EUR ancestry FINEMAP results were used as input for flashfm. Default parameters were used, except a prior odds of 80% (TOdds=0.25) of a shared causal variant across traits was used. 99CS were used to compare single-trait and flashfm results. Flashfm successfully fine-mapped 48 loci (106 locus-trait associations, 5 loci could not be run). At 40/106 locus-trait associations flashfm led to 99CS with ≤10 SNPs, of which 4 had a single SNP, prioritising SNPs for functional follow-up. Fine-mapping across ≥2 traits reduced the number of SNPs in the 99CS in 80.1% (85/106) of locus-trait associations. The median number of SNPs in the 99CS were significantly reduced from 50 to 19 (p=1.1 x10-13). In 47.3% (44/93) of locus-trait associations flashfm reduced the 99CS size compared to TA fine-mapping. Our results show that leveraging data across multiple related traits is a useful approach to improve single-ancestry fine-mapping resolution, and that it may also improve TA fine-mapping.

Disclosure

J. Soenksen: None. J. Chen: None. J. L. Asimit: None. Magic: n/a. I. Barroso: Stock/Shareholder; Self; Incyte Corporation, Stock/Shareholder; Spouse/Partner; GlaxoSmithKline plc.

Funding

Research England; Medical Research Council (MR/R021368/1)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.